皮损内注射利妥昔单抗治疗皮肤B细胞淋巴瘤。

Intralesional rituximab for cutaneous B-cell lymphoma.

作者信息

Paul T, Radny P, Kröber S M, Paul A, Blaheta H J, Garbe C

机构信息

Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, D-72076 Tübingen, Germany.

出版信息

Br J Dermatol. 2001 Jun;144(6):1239-43. doi: 10.1046/j.1365-2133.2001.04241.x.

DOI:10.1046/j.1365-2133.2001.04241.x

PMID:11422050

Abstract

Rituximab, a chimeric anti-CD20 monoclonal antibody, has been approved for systemic treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. As cutaneous B-cell lymphoma (CBCL) also expresses the CD20 molecule, three patients with histologically and immunohistochemically confirmed CBCL without systemic involvement were treated with low-dose intralesional rituximab in a pilot study. Single doses applied ranged from 10 to 30 mg per lesion, according to lesion extent, with a cumulative dose of up to 350 mg. Injections were given two or three times weekly for 3-5 weeks, with a second cycle after 6 weeks in one patient with incomplete remission. Complete and lasting remission was achieved in each patient; this has persisted for up to more than 1 year. The observed adverse events were of grade 1 severity. Results suggest that intralesional rituximab may be a safe and effective new therapy modality for CBCL.

摘要

利妥昔单抗是一种嵌合抗CD20单克隆抗体，已被批准用于复发性或难治性CD20阳性B细胞非霍奇金淋巴瘤的全身治疗。由于皮肤B细胞淋巴瘤（CBCL）也表达CD20分子，在一项初步研究中，对3例经组织学和免疫组织化学证实无全身受累的CBCL患者采用低剂量病灶内注射利妥昔单抗进行治疗。根据病灶范围，每个病灶的单剂量为10至30mg，累积剂量最高可达350mg。每周注射两到三次，持续3至5周，1例未完全缓解的患者在6周后进行了第二个疗程。每位患者均实现了完全且持久的缓解；这种缓解持续了长达1年多。观察到的不良事件为1级严重程度。结果表明，病灶内注射利妥昔单抗可能是一种治疗CBCL的安全有效的新治疗方式。